Cellular immunotherapy for hematological malignancy: recent progress and future perspectives

Advancements in the field of cellular immunotherapy have accelerated in recent years and have changed the treatment landscape for a variety of hematologic malignancies. Cellular immunotherapy strategies exploit the patient’s immune system to kill cancer cells. The successful use of CD19 chimeric ant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhengli Xu, Xiaojun Huang
Formato:	article
Lenguaje:	EN
Publicado:	China Anti-Cancer Association 2021
Materias:	cellular immunotherapy hematologic car-t nk stem cell transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/96e553b7917b447ba42b7368cc8e3bf6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:96e553b7917b447ba42b7368cc8e3bf6
record_format	dspace
spelling	oai:doaj.org-article:96e553b7917b447ba42b7368cc8e3bf62021-11-30T11:27:44ZCellular immunotherapy for hematological malignancy: recent progress and future perspectives2095-394110.20892/j.issn.2095-3941.2020.0801https://doaj.org/article/96e553b7917b447ba42b7368cc8e3bf62021-11-01T00:00:00Zhttp://www.cancerbiomed.org/index.php/cocr/article/view/1884https://doaj.org/toc/2095-3941Advancements in the field of cellular immunotherapy have accelerated in recent years and have changed the treatment landscape for a variety of hematologic malignancies. Cellular immunotherapy strategies exploit the patient’s immune system to kill cancer cells. The successful use of CD19 chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies is the paradigm of this revolution, and numerous ongoing studies are investigating and extending this approach to other malignancies. However, resistance to CAR-T-cell therapy and non-durable efficacy have prevented CAR-T-cells from becoming the ultimate therapy. Because natural killer (NK) cells play an essential role in antitumor immunity, adoptively transferred allogeneic NK and CAR-modified NK cell therapy has been attempted in certain disease subgroups. Allogenic hematopoietic stem cell transplantation (allo-HSCT) is the oldest form of cellular immunotherapy and the only curative option for hematologic malignancies. Historically, the breadth of application of allo-HSCT has been limited by a lack of identical sibling donors (ISDs). However, great strides have recently been made in the success of haploidentical allografts worldwide, which enable everyone to have a donor. Haploidentical donors can achieve comparable outcomes to those of ISDs and even better outcomes in certain circumstances because of a stronger graft vs. tumor effect. Currently, novel strategies such as CAR-T or NK-based immunotherapy can be applied as a complement to allo-HSCT for curative effects, particularly in refractory cases. Here, we introduce the developments in cellular immunotherapy in hematology.Zhengli XuXiaojun HuangChina Anti-Cancer Associationarticlecellular immunotherapyhematologiccar-tnkstem cell transplantationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Biology & Medicine, Vol 18, Iss 4, Pp 966-980 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cellular immunotherapy hematologic car-t nk stem cell transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cellular immunotherapy hematologic car-t nk stem cell transplantation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zhengli Xu Xiaojun Huang Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
description	Advancements in the field of cellular immunotherapy have accelerated in recent years and have changed the treatment landscape for a variety of hematologic malignancies. Cellular immunotherapy strategies exploit the patient’s immune system to kill cancer cells. The successful use of CD19 chimeric antigen receptor (CAR) T-cells in treating B-cell malignancies is the paradigm of this revolution, and numerous ongoing studies are investigating and extending this approach to other malignancies. However, resistance to CAR-T-cell therapy and non-durable efficacy have prevented CAR-T-cells from becoming the ultimate therapy. Because natural killer (NK) cells play an essential role in antitumor immunity, adoptively transferred allogeneic NK and CAR-modified NK cell therapy has been attempted in certain disease subgroups. Allogenic hematopoietic stem cell transplantation (allo-HSCT) is the oldest form of cellular immunotherapy and the only curative option for hematologic malignancies. Historically, the breadth of application of allo-HSCT has been limited by a lack of identical sibling donors (ISDs). However, great strides have recently been made in the success of haploidentical allografts worldwide, which enable everyone to have a donor. Haploidentical donors can achieve comparable outcomes to those of ISDs and even better outcomes in certain circumstances because of a stronger graft vs. tumor effect. Currently, novel strategies such as CAR-T or NK-based immunotherapy can be applied as a complement to allo-HSCT for curative effects, particularly in refractory cases. Here, we introduce the developments in cellular immunotherapy in hematology.
format	article
author	Zhengli Xu Xiaojun Huang
author_facet	Zhengli Xu Xiaojun Huang
author_sort	Zhengli Xu
title	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
title_short	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
title_full	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
title_fullStr	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
title_full_unstemmed	Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
title_sort	cellular immunotherapy for hematological malignancy: recent progress and future perspectives
publisher	China Anti-Cancer Association
publishDate	2021
url	https://doaj.org/article/96e553b7917b447ba42b7368cc8e3bf6
work_keys_str_mv	AT zhenglixu cellularimmunotherapyforhematologicalmalignancyrecentprogressandfutureperspectives AT xiaojunhuang cellularimmunotherapyforhematologicalmalignancyrecentprogressandfutureperspectives
_version_	1718406637314637824

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives

Ejemplares similares